サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1648907

デュシェンヌ型筋ジストロフィー治療薬の世界市場

Duchenne Muscular Dystrophy Drugs

出版日
ページ情報
英文 220 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
デュシェンヌ型筋ジストロフィー治療薬の世界市場
出版日: 2025年02月04日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 220 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

デュシェンヌ型筋ジストロフィー治療薬の世界市場は2030年までに297億米ドルに到達

2024年に44億米ドルと推定されるデュシェンヌ型筋ジストロフィー治療薬の世界市場は、2024～2030年の分析期間においてCAGR 37.7%で成長し、2030年には297億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるエクソンスキッピング療法は、CAGR 42.6%を記録し、分析期間終了までに197億米ドルに達すると予測されます。ステロイド療法分野の成長率は、分析期間中CAGR26.5%と推定されます。

米国市場は18億米ドルと推定、中国はCAGR43.6％で成長予測

米国のデュシェンヌ型筋ジストロフィー治療薬市場は、2024年に18億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに24億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは43.6％となります。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ30.9%と30.0%と予測されています。欧州では、ドイツがCAGR約32.5%で成長すると予測されています。

世界のデュシェンヌ型筋ジストロフィー治療薬市場- 主要動向と促進要因まとめ

デュシェンヌ型筋ジストロフィーとその影響とは？

デュシェンヌ型筋ジストロフィー（DMD）は、進行性の筋変性と筋力低下を特徴とする重篤な遺伝性疾患です。主に男児に発症し、通常2～5歳の間に症状が現れます。この疾患は、筋肉の機能に不可欠なジストロフィン遺伝子の突然変異によって引き起こされます。ジストロフィンが欠損すると筋線維が損傷し、最終的には脂肪や結合組織に置き換わる。DMDが進行すると、歩けなくなり、呼吸器や心臓の合併症を引き起こし、生命予後が著しく短くなります。患者さんやご家族への影響は甚大であり、継続的な医療ケアとサポートが必要となります。

治療アプローチはどのように進化しているのか？

デュシェンヌ型筋ジストロフィーの治療アプローチは、遺伝子治療、分子治療薬、対症療法などの進歩により、急速に進化しています。歴史的には、副腎皮質ステロイドがDMD治療の中心であり、筋肉の変性を遅らせるのに役立ってきました。しかし近年、DMDの根本的な遺伝的原因に対処することを目的とした遺伝子治療やエクソンスキッピング薬が大きく進歩しています。これらの革新的な治療法は、欠損したジストロフィン遺伝子を回復または置換するように設計されており、より効果的で長期にわたる治療効果が期待できます。さらに、理学療法、呼吸ケア、心臓管理などの支持療法は、生活の質を改善し、疾患合併症を管理するために引き続き重要です。

臨床試験と薬事承認はどのような役割を果たすのか？

臨床試験と薬事承認は、デュシェンヌ型筋ジストロフィーに対する新しい治療法の開発と利用可能性において極めて重要です。新しい治療法の安全性と有効性を実証するためには、厳格な臨床試験が不可欠です。このような臨床試験には複数の段階が含まれることが多く、研究者、ヘルスケアプロバイダー、患者の協力が必要となります。FDAやEMAなどの規制機関は、新薬の評価と承認において重要な役割を担っており、新薬が厳しい安全性と有効性の基準を満たしていることを保証しています。DMDのような希少疾患の治療開発を促進するために、早期承認パスウェイや希少疾病用医薬品の指定がしばしば利用され、有望な治療法を早期に患者に提供しています。

市場成長の要因は何か？

デュシェンヌ型筋ジストロフィー治療薬市場の成長は、遺伝子研究の進歩、資金や投資の増加、疾患の有病率の上昇など、いくつかの要因によってもたらされます。遺伝子編集や分子生物学における技術革新は、より的を絞った効果的な治療への道を開いています。政府、非営利団体、製薬会社からの資金提供の増加は、研究開発の努力を加速させています。また、DMDに対する認識と診断の高まりも、治療を求める患者の増加に伴い、市場の成長に寄与しています。さらに、バイオテクノロジー企業と学術機関の連携が、革新的な治療法の開発を促進しています。希少疾病用医薬品の早期承認に向けたイニシアチブを持つ規制環境は、DMD患者の予後改善に希望をもたらし、市場拡大をさらに後押ししています。

セグメント

セグメント（エクソンスキッピング,ステロイド療法,変異抑制,その他のセグメント）

調査対象企業の例（全38件）

  • FibroGen, Inc.
  • ITALFARMACO S.p.A.
  • NS Pharma Inc.
  • PTC Therapeutics, Inc.
  • Sarepta Therapeutics, Inc.
  • Satellos Bioscience, Inc.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP11652

Global Duchenne Muscular Dystrophy Drugs Market to Reach US$29.7 Billion by 2030

The global market for Duchenne Muscular Dystrophy Drugs estimated at US$4.4 Billion in the year 2024, is expected to reach US$29.7 Billion by 2030, growing at a CAGR of 37.7% over the analysis period 2024-2030. Exon Skipping Therapy, one of the segments analyzed in the report, is expected to record a 42.6% CAGR and reach US$19.7 Billion by the end of the analysis period. Growth in the Steroid Therapy segment is estimated at 26.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.8 Billion While China is Forecast to Grow at 43.6% CAGR

The Duchenne Muscular Dystrophy Drugs market in the U.S. is estimated at US$1.8 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.4 Billion by the year 2030 trailing a CAGR of 43.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 30.9% and 30.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 32.5% CAGR.

Global Duchenne Muscular Dystrophy Drugs Market - Key Trends & Drivers Summarized

What Is Duchenne Muscular Dystrophy and Its Impact?

Duchenne Muscular Dystrophy (DMD) is a severe genetic disorder characterized by progressive muscle degeneration and weakness. It primarily affects boys, with symptoms typically appearing between the ages of two and five. The disease is caused by mutations in the dystrophin gene, which is essential for muscle function. Without dystrophin, muscle fibers are damaged and eventually replaced by fat and connective tissue. The progression of DMD leads to loss of ambulation, respiratory and cardiac complications, and significantly reduced life expectancy. The impact on patients and their families is profound, necessitating ongoing medical care and support.

How Are Treatment Approaches Evolving?

Treatment approaches for Duchenne Muscular Dystrophy are evolving rapidly, with advancements in genetic therapies, molecular drugs, and symptomatic treatments. Historically, corticosteroids have been the mainstay of DMD treatment, helping to slow muscle degeneration. However, recent years have seen significant progress in gene therapy and exon-skipping drugs, which aim to address the underlying genetic causes of DMD. These innovative therapies are designed to restore or replace the defective dystrophin gene, offering the potential for more effective and long-lasting treatment outcomes. Additionally, supportive therapies such as physical therapy, respiratory care, and cardiac management remain crucial for improving quality of life and managing disease complications.

What Role Do Clinical Trials and Regulatory Approvals Play?

Clinical trials and regulatory approvals are pivotal in the development and availability of new treatments for Duchenne Muscular Dystrophy. Rigorous clinical trials are essential for demonstrating the safety and efficacy of new therapies. These trials often involve multiple phases and require collaboration between researchers, healthcare providers, and patients. Regulatory bodies, such as the FDA and EMA, play a critical role in evaluating and approving new drugs, ensuring that they meet stringent safety and effectiveness standards. Accelerated approval pathways and orphan drug designations are often utilized to expedite the development of treatments for rare diseases like DMD, providing patients with earlier access to promising therapies.

What Factors Are Driving Market Growth?

The growth in the Duchenne Muscular Dystrophy drugs market is driven by several factors, including advancements in genetic research, increased funding and investment, and the rising prevalence of the disease. Technological innovations in gene editing and molecular biology are paving the way for more targeted and effective treatments. Increased funding from governments, non-profit organizations, and pharmaceutical companies is accelerating research and development efforts. The rising awareness and diagnosis of DMD are also contributing to market growth, as more patients seek treatment. Additionally, collaborations between biotech firms and academic institutions are fostering the development of innovative therapies. The regulatory environment, with initiatives to fast-track the approval of orphan drugs, is further supporting market expansion, providing hope for improved outcomes for patients with DMD.

SCOPE OF STUDY:

The report analyzes the Duchenne Muscular Dystrophy Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Segment (Exon Skipping, Steroid Therapy, Mutation Suppression, Other Segments)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 38 Featured) -

  • FibroGen, Inc.
  • ITALFARMACO S.p.A.
  • NS Pharma Inc.
  • PTC Therapeutics, Inc.
  • Sarepta Therapeutics, Inc.
  • Satellos Bioscience, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • A Prelude to Duchenne Muscular Dystrophy
    • Global Economic Update
    • Here's How Inflationary Pressures Affect the Economy
    • Here's What's Causing Inflationary Pressures in the Global Market
    • World Economic Growth Projections (Real GDP, Annual % Change) for the Years 2020 Through 2024
    • Competition
    • Product Development as Hallmark of Global Duchenne Muscular Dystrophy Market
    • Duchenne Muscular Dystrophy Drugs - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
    • Global Market Overview and Prospects
    • Global Duchenne Muscular Dystrophy Drugs Market Set for a Rapid Growth, Driven by Rising Prevalence
    • A Review of the Approved DMD Drugs
    • North America and Europe to Remain Lucrative Markets
    • Molecular Therapy, Hospital/Clinic & Hospital Pharmacy: Hale & Hearty Segments of Duchenne Muscular Dystrophy Market
    • Dynamic Factors Keeping Duchenne Muscular Dystrophy Market Growing
    • Market Drivers
    • Rising Incidence of DMD to Catalyze Growth
    • DMD Prevalence (in 100,000 Population) in Select Countries: 2020
    • High Uptake of Novel Therapies & Drugs
    • Market Restraints & Challenges
    • Lack of Standardization for Clinical Efficacy
    • Stringent Regulatory Regime
    • Market Opportunities
    • Product Developments & Rising Awareness
    • Surge in Clinical Trials to Launch Novel Options
    • Recent Market Activity
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising R&D Investment to Boost DMD Market
    • Select Therapy Candidates Under Development for Treating DMD
    • Growing Government Support Propels Market Expansion
    • Biologics - The Most Dynamic Segment of the Market
    • Blossoming of Gene Therapy in Duchenne Muscular Dystrophy Treatment Domain
    • Gene Therapy for DMD Treatment
    • Elevidys, The First Ground-breaking Gene Therapy for Treatment of Duchenne Muscular Dystrophy (DMD)
    • Children's National Hospital Starts Offering Newly Approved Gene Therapy for DMD
    • Promising Gene Therapies
    • Potential Side-Effects & Risks of Gene Therapies
    • Vamorolon Holds Potential to Lessen Health Risks Linked with Extended Use of Steriods
    • DT-DEC01 Offers Promise to Stabilize or Improve Motor Function
    • AOC 1044 Receives Orphan Drug Status for DMD44
    • Italfarmaco Group Announces NDA Acceptance for Givinostat Targeting Duchenne Muscular Dystrophy
    • Uptrend in Healthcare Expenditure Creates Substantial Opportunities
    • World Healthcare Expenditure (In US$ Trillion) for the Years 2019, 2021 & 2023
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Duchenne Muscular Dystrophy Drugs Market Analysis of Annual Sales in US$ Thousand for Years 2018 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Duchenne Muscular Dystrophy Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2023 and % CAGR
    • TABLE 4: World 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2018, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Exon Skipping by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Exon Skipping by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2023 and % CAGR
    • TABLE 7: World 12-Year Perspective for Exon Skipping by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2018, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Steroid Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Steroid Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2023 and % CAGR
    • TABLE 10: World 12-Year Perspective for Steroid Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2018, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other Therapeutic Approaches by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Other Therapeutic Approaches by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2023 and % CAGR
    • TABLE 13: World 12-Year Perspective for Other Therapeutic Approaches by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2018, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2023 and % CAGR
    • TABLE 16: World 12-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2018, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Drug Store & Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Drug Store & Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2023 and % CAGR
    • TABLE 19: World 12-Year Perspective for Drug Store & Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2018, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2023 and % CAGR
    • TABLE 22: World 12-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2018, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • TABLE 23: USA Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2023 and % CAGR
    • TABLE 25: USA 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Percentage Breakdown of Value Sales for Exon Skipping, Steroid Therapy and Other Therapeutic Approaches for the Years 2018, 2025 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2023 and % CAGR
    • TABLE 28: USA 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies for the Years 2018, 2025 & 2030
  • CANADA
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2023 and % CAGR
    • TABLE 31: Canada 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Percentage Breakdown of Value Sales for Exon Skipping, Steroid Therapy and Other Therapeutic Approaches for the Years 2018, 2025 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2023 and % CAGR
    • TABLE 34: Canada 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies for the Years 2018, 2025 & 2030
  • JAPAN
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2023 and % CAGR
    • TABLE 37: Japan 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Percentage Breakdown of Value Sales for Exon Skipping, Steroid Therapy and Other Therapeutic Approaches for the Years 2018, 2025 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2023 and % CAGR
    • TABLE 40: Japan 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies for the Years 2018, 2025 & 2030
  • CHINA
    • TABLE 41: China Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2023 and % CAGR
    • TABLE 43: China 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Percentage Breakdown of Value Sales for Exon Skipping, Steroid Therapy and Other Therapeutic Approaches for the Years 2018, 2025 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2023 and % CAGR
    • TABLE 46: China 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies for the Years 2018, 2025 & 2030
  • EUROPE
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Duchenne Muscular Dystrophy Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2023 and % CAGR
    • TABLE 49: Europe 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2018, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2023 and % CAGR
    • TABLE 52: Europe 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Percentage Breakdown of Value Sales for Exon Skipping, Steroid Therapy and Other Therapeutic Approaches for the Years 2018, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2023 and % CAGR
    • TABLE 55: Europe 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies for the Years 2018, 2025 & 2030
  • FRANCE
    • TABLE 56: France Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2023 and % CAGR
    • TABLE 58: France 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Percentage Breakdown of Value Sales for Exon Skipping, Steroid Therapy and Other Therapeutic Approaches for the Years 2018, 2025 & 2030
    • TABLE 59: France Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2023 and % CAGR
    • TABLE 61: France 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies for the Years 2018, 2025 & 2030
  • GERMANY
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2023 and % CAGR
    • TABLE 64: Germany 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Percentage Breakdown of Value Sales for Exon Skipping, Steroid Therapy and Other Therapeutic Approaches for the Years 2018, 2025 & 2030
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2023 and % CAGR
    • TABLE 67: Germany 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies for the Years 2018, 2025 & 2030
  • ITALY
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2023 and % CAGR
    • TABLE 70: Italy 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Percentage Breakdown of Value Sales for Exon Skipping, Steroid Therapy and Other Therapeutic Approaches for the Years 2018, 2025 & 2030
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2023 and % CAGR
    • TABLE 73: Italy 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies for the Years 2018, 2025 & 2030
  • UNITED KINGDOM
    • TABLE 74: UK Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2023 and % CAGR
    • TABLE 76: UK 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Percentage Breakdown of Value Sales for Exon Skipping, Steroid Therapy and Other Therapeutic Approaches for the Years 2018, 2025 & 2030
    • TABLE 77: UK Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2023 and % CAGR
    • TABLE 79: UK 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies for the Years 2018, 2025 & 2030
  • REST OF EUROPE
    • TABLE 80: Rest of Europe Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Rest of Europe Historic Review for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2023 and % CAGR
    • TABLE 82: Rest of Europe 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Percentage Breakdown of Value Sales for Exon Skipping, Steroid Therapy and Other Therapeutic Approaches for the Years 2018, 2025 & 2030
    • TABLE 83: Rest of Europe Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Rest of Europe Historic Review for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2023 and % CAGR
    • TABLE 85: Rest of Europe 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies for the Years 2018, 2025 & 2030
  • ASIA-PACIFIC
    • TABLE 86: Asia-Pacific Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Asia-Pacific Historic Review for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2023 and % CAGR
    • TABLE 88: Asia-Pacific 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Percentage Breakdown of Value Sales for Exon Skipping, Steroid Therapy and Other Therapeutic Approaches for the Years 2018, 2025 & 2030
    • TABLE 89: Asia-Pacific Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Asia-Pacific Historic Review for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2023 and % CAGR
    • TABLE 91: Asia-Pacific 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies for the Years 2018, 2025 & 2030
  • REST OF WORLD
    • TABLE 92: Rest of World Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of World Historic Review for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2023 and % CAGR
    • TABLE 94: Rest of World 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Percentage Breakdown of Value Sales for Exon Skipping, Steroid Therapy and Other Therapeutic Approaches for the Years 2018, 2025 & 2030
    • TABLE 95: Rest of World Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of World Historic Review for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2023 and % CAGR
    • TABLE 97: Rest of World 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies for the Years 2018, 2025 & 2030

IV. COMPETITION